Understanding value requires studying the assets underpinning firm valuation, not commodity production.
Evidence
As the above discussion should indicate, value needs rethinking in order to understand what gets valued (i.e., firm) and how (i.e., valuation practices); this, however, necessitates an examination of the coproduction of these practices with organizational forms and their governance. Understanding value in relation to organizational entities means focusing on (organizational) assets—which underpin their valuation—as opposed to commodity production. At present, most STS scholarship on the bio-economy has focused analytically on commodity production and the commodification of life, tissues, knowledge, and so on. This emphasis is, at least partly, the result of a concern with contrasting gift economies and commodification (e.g., Tutton 2011). — Kean Birch, Rethinking Value in the Bio-economy, 39
Categorization
- ADDENDUM: Directly supports the assetization debate that the reader is studying; reframes bio-economy scholarship from commodification to assetization.
- XREF: connects to: Life sciences firms may never produce products, so valuation is prospective rather than embodied — Kean Birch, Rethinking Value in the Bio-economy:…, 38; Understanding value as assetization requires analyzing political economy, not just applying STS to finance. — Kean Birch, Rethinking Value in the Bio-economy:…, 115; In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. — Kean Birch, Rethinking Value in the Bio-economy:…, 106 (+2 more)
Related
- Value in the bio-economy is managed through asset governance, not product sales. (similarity 0.94)
- Analyzing bio-economy value requires focusing on assets rather than commodities (similarity 0.94)
- Value in the bio-economy is better theorized through assetization than commodification. (similarity 0.92)
- In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value. (similarity 0.91)
- Asset value is constituted by active management within organizations, not by biological properties. (similarity 0.90)
- Asset value derives from future earnings rather than intrinsic commodity value (similarity 0.88)
- Value in the bio-economy is produced through valuation practices, not intrinsic to biological matter. (similarity 0.88)
- Life sciences firms may never produce products, so valuation is prospective rather than embodied (similarity 0.88)
- Bio-economy valuation practices are not peculiar to that sector. (similarity 0.87)
- Value is not inherent in things but achieved through capitalization practices. (similarity 0.86)
- Understanding value as assetization requires analyzing political economy, not just applying STS to finance. (similarity 0.86)
- Value is constituted by knowledge and practice, not merely hype. (similarity 0.85)
- Accounting for biological assets reflects chosen methods, not intrinsic biological qualities (similarity 0.84)
- Asset value is actively managed, including downward, and its constructedness is obscured. (similarity 0.83)
- Capitalization builds the thing being valued at the same time it appraises that thing (similarity 0.82)
Broader Connections
- In the bioeconomy, informational signaling about assets, not product sales, constitutes firm value.
#corroborates(0.85) — Kean Birch, Rethinking Value in the Bio-economy, 106 - Analyzing bio-economy value requires focusing on assets rather than commodities
#corroborates(0.85) — Kean Birch, Rethinking Value in the Bio-economy, 68 - Understanding value as assetization requires analyzing political economy, not just applying STS to finance.
#expands(0.80) — Kean Birch, Rethinking Value in the Bio-economy, 115 - Value in the bio-economy is managed through asset governance, not product sales.
#corroborates(0.80) — Kean Birch, Rethinking Value in the Bio-economy, 88